Cyclerion Therapeutics, Inc. (CYCN)
NASDAQ: CYCN · IEX Real-Time Price · USD
3.310
+0.190 (6.09%)
Jul 19, 2024, 4:00 PM EDT - Market closed
Company Description
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases.
It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease.
The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Cyclerion Therapeutics, Inc.
Country | United States |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 1 |
CEO | Dr. Regina Graul Ph.D. |
Contact Details
Address: 301 Binney Street Cambridge, Massachusetts 02142 United States | |
Phone | 617-621-7722 |
Website | cyclerion.com |
Stock Details
Ticker Symbol | CYCN |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001755237 |
CUSIP Number | 23255M105 |
ISIN Number | US23255M2044 |
Employer ID | 83-1895370 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Regina Graul Ph.D. | President |
Rhonda M. Chicko | Chief Financial Officer |
Dr. Todd Milne Ph.D. | Senior Vice President of External Innovation |
Jessica Rennekamp | Associate Director of Corporate Communications |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jul 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Jun 14, 2024 | 8-K | Current Report |
May 7, 2024 | 10-Q | Quarterly Report |
Apr 29, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Apr 29, 2024 | DEF 14A | Other definitive proxy statements |
Apr 18, 2024 | 8-K | Current Report |
Mar 5, 2024 | 10-K | Annual Report |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 9, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 9, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |